ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
-0.022 (-2.98%)
Oct 20 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.70 - 0.74
52 week 0.65 - 4.00
Open 0.74
Vol / Avg. 310,454.00/356,454.00
Mkt cap 44.72M
P/E     -
Div/yield     -
EPS -0.16
Shares 60.67M
Beta 1.11
Inst. own 7%
Nov 3, 2014
Q3 2014 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 1, 2014
ImmunoCellular Therapeutics Ltd at Livingston Securities Life Sciences Stakeholders Summit
Aug 7, 2014
Q2 2014 ImmunoCellular Therapeutics Ltd Earnings Call
Aug 7, 2014
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.02% -31.45%
Return on average equity -36.56% -35.53%
Employees 3 -
CDP Score - -


Suite 300, 23622 Calabasas Road
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Officers and directors

John S. Yu M.D. Chairman of the Board, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Andrew Gengos President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 60
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 54
Bio & Compensation  - Reuters